Structure-activity relationship studies of isoquinolinone type anticancer agent

[1]  J. Y. Lee,et al.  Studies on the synthesis andin vitro antitumor activity of the isoquinolone derivatives , 1999, Archives of pharmacal research.

[2]  M. Threadgill,et al.  Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). , 1998, Bioorganic & medicinal chemistry.

[3]  Sang-Un Choi,et al.  Synthesis and structure-activity relationship studies of substituted isoquinoline analogs as antitumor agent , 1998, Archives of pharmacal research.

[4]  B. Kang,et al.  Synthesis and structure-activity relationship studies of 2,3-dihydroimidazo[2,1-a]isoquinoline analogs as antitumor agents , 1997, Archives of pharmacal research.

[5]  R. Gould,et al.  Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. , 1996, Journal of medicinal chemistry.

[6]  M. Threadgill,et al.  Labelled compounds of interest as antitumour agents-v1. Syntheses of [18O]-5-methylisoquinolinone and 1-(furan-2-yl-[18O]-methoxy)-5-methylisoquinoline , 1996 .

[7]  B. Kang,et al.  Synthesis of benzo[c]phenanthridine derivatives and theirin vitro antitumor activities , 1996 .

[8]  D. Handley,et al.  Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinoline. , 1995, Arzneimittel-Forschung.

[9]  D. Handley,et al.  Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines. , 1995, Journal of medicinal chemistry.

[10]  D. Handley,et al.  Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. , 1993, Journal of medicinal chemistry.

[11]  P. Workman,et al.  In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. , 1993, British Journal of Cancer.

[12]  P. Workman.  Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity. , 1991, Cancer cells.

[13]  H. Grunicke,et al.  Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. , 1991, Cancer research.

[14]  P. Workman,et al.  Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells. , 1991, Cancer research.

[15]  W. Berdel,et al.  Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. , 1991, Cancer research.

[16]  E. Modest,et al.  Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. , 1990, Cancer research.

[17]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[18]  L V Rubinstein,et al.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. , 1990, Journal of the National Cancer Institute.

[19]  O. Westphal,et al.  Antitumoral and Other Biomedical Activities of Synthetic Ether Lysophospholipids (Part 1 of 2) , 1990 .

[20]  O. Westphal,et al.  Antitumoral and other biomedical activities of synthetic ether lysophospholipids. , 1990, Chemical immunology.

[21]  E. Modest,et al.  Effects of antineoplastic ether lipids on model and biological membranes. , 1988, Biochimica et biophysica acta.

[22]  W. Berdel,et al.  Antineoplastic Actions of Ether Lipids Related to Platelet-Activating Factor , 1987 .

[23]  V. Parrino,et al.  Directed lithiation of 2-phenyl- and 2-(o-methylphenyl)imidazoline , 1982 .

[24]  G. Poindexter.  Convenient preparation of 3-substituted 1(2H)-isoquinolinones , 1982 .

[25]  W. C. Still,et al.  Rapid chromatographic technique for preparative separations with moderate resolution , 1978 .